亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy

        2014-12-08 08:14:50TammySAAHStevenGARLOWMarkRAPAPORT
        上海精神醫(yī)學(xué) 2014年6期
        關(guān)鍵詞:單藥抗抑郁精神科

        Tammy SAAH*, Steven J. GARLOW, Mark H. RAPAPORT

        Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy

        Tammy SAAH*, Steven J. GARLOW, Mark H. RAPAPORT

        antidepressants; polypharmacy; augmentation; major depressive disorder; treatment-resistant depression

        Major depressive disorder (MDD) is a chronic recurrent condition. With the advent of efficacious antidepressants in the 1950s and 1960s, the treatment paradigm for this disorder shifted dramatically. There are now a large number of antidepressants with clear benefits in the treatment of MDD, but – given the chronic and recurring nature of this syndrome –many patients have suboptimal responses to these medications. When confronted with these patients,clinicians often resort to augmention of a primary antidepressant with other medications, including second and third antidepressant medications. Sometimes a second antidepressant is used to target a specific symptom, such as using trazodone or mirtazapine for sleep, but at other times the second antidepressant is to improve the overall therapeutic outcome. While these practices are common, the evidence to support polypharmacy with antidepressants to improve efficacy is minimal.

        Combining antidepressants may be useful in some special cases, but there is little evidence to support making this a standard approach for managing treatment-resistant depression. The potential benefits of antidepressant polypharmacy include potentiation of the partial effectiveness of the initial monotherapy regimen, particularly in resistant depressive cases that show limited benefit from multiple monotherapy switch treatments. Most of the benefit of this type of polypharmacy occurs in individuals with unipolar depression. Various risks of antidepressant polypharmacy include: (a) drug-drug interactions and the impact on medication metabolism; (b) the potential for increased adverse effects, increased rates of treatment-emergent mania, or cycling of bipolar affective patients; (c) increased financial burden; and (d)increased risk of patients’ medication errors.

        Despite the absence of robust evidence, antidepressant polypharmacy has become commonplace among psychiatrists in high-income countries,particularly among patients classified as ‘treatmentresistant’ due to failure of multiple monotherapy trials.In a study of office-based psychiatric practices between 1996 and 2006 based on the National Ambulatory Medical Care Survey,[1]polypharmacy with two ormore antidepressants was disproportionately more common among adults 45 to 64 years of age versus those 18 to 44, and it was significantly more common in women than in men. In a separate chart review of 135 patients,[2]antidepressant polypharmacy was no better than antidepressant monotherapy in terms of medication response (based on changes in the Clinical Global Impressions Scale (CGI) score), clinical response,or remission rates. This paper also reported that many of the monotherapy trials patients had received prior to ‘graduating’ to antidepressant polypharmacy were inadequate either in dose or duration. This lends to the concern that general psychiatric practitioners may initiate polypharmacy prematurely, before the effectiveness of monotherapy is fully tested.

        The combination of mirtazapine and venlafaxine –termed ‘California rocket fuel’ – was widely publicized as an effective regimen for treatment-resistant depression. A little over a decade ago, this set off a popular trend among clinicians of utilizing multiple adjunct antidepressants to treat recurrent and severe depression. However, data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)study[3]did not find significantly increased remission rates of patients taking the mirtazapine plus venlafaxine combination versus those on monotherapy with tranylcypromine. However, the side effect profiles and overall tolerability were more favorable with the combination regimen than when using a monoamine oxidase inhibitor. The more recent large-scale Combining Medications to Enhance Depression Outcomes (COMED) study[4]again failed to show that antidepressant polypharmacy was superior to antidepressant monotherapy.

        The prevalence of antidepressant use among adults in the community in the United States has increased 3-to 4-fold over the last 15 years, reaching an astounding 8-10% of the adult population by 2010.[5]Despite the lack of evidence of effectiveness of antidepressant polypharmacy, as part of this general increase in the use of antidepressants, antidepressant polypharmacy has also increased. Healthplan database reviews in 2011 found that antidepressant polypharmacy was present in 2% of 1615 older adults participating in the health plan and in 3% of 4854 younger adults.[6]

        Although it is a widely-used practice among psychiatrists and primary care physicians in highincome countries, given the very limited evidence of effectiveness, care should be taken to limit use of antidepressant polypharmacy approaches to the very small number of cases that have failed optimized monotherapy with a variety of antidepressants from different classes. For patients who continue to demonstrate treatment resistance after multiple adequate monotherapy trials, alternative treatment modalities should probably be consideredbeforeresorting to antidepressant polypharmacy. These alternative approaches include electroconvulsive therapy (ECT), transcranial magnetic stimulation (rTMS),and ketamine, all of which – unlike antidepressant polypharmacy – have shown efficacy in treatmentresistant patients. These alternative treatments have very different mechanisms of action so, unlike antidepressant polypharmacy, they may be able to overcome treatment resistance that develops to conventional antidepressant agents.

        Conflict of Interest

        The authors report no conflict of interest related to this manuscript.

        Funding

        1. Shelton RC, Osuntokun O, Heinloth AN, Corya SA.Therapeutic options for treatment-resistant depression.CNS drugs. 2010; 24(2): 131-161. Epub 2010 Jan 22. doi: http://dx.doi.org/10.2165/11530280-000000000-00000

        2. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry.Arch Gen Psychiatry. 2010; 67(1): 26-36. Epub 2010 Jan 06. doi:http://dx.doi.org/10.1001/archgenpsychiatry.2009.175

        3. Glezer A, Byatt N, Cook R, Jr., Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.J Affect Disorders. 2009; 117(1-2):18-23. Epub 2008 Dec 24. doi: http://dx.doi.org/10.1016/j.jad.2008.11.016

        4. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR,Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.Am J Psychiatry.2006; 163(9): 1531-1541. Epub 2006 Sep 02

        5. Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. A systematic review of treatments for refractory depression in older people.Am J Psychiatry. 2011; 168(7):681-8. Epub 2011 Apr 02

        6. Warden D, Trivedi MH, Carmody T, Toups M, Zisook S,Lesser I, et.al. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a COMED report of measurement-based care.J Psychiatr Pract.2014; 20(2): 118-132. Epub 2014 Mar 19. doi: http://dx.doi.org/10.1097/01.pra.0000445246.46424.fe

        7. Milea D, Verpillat P, Guelfucci F, Toumi M, Lamure M. Prescription patterns of antidepressants: findings from a US claims database.Curr Med Res Opin. 2010;26(6): 1343-53. Epub 2010 Apr 09. doi: http://dx.doi.org/10.1185/03007991003772096

        8. Sanglier T, Saragoussi D, Milea D, Auray JP, Valuck RJ,Tournier M. Comparing antidepressant treatment patterns in older and younger adults: a claims database analysis.J Am Geriatr Soc.2011; 59(7): 1197-1205. Epub 2011 Jul 02. doi:http://dx.doi.org/10.1111/j.1532-5415.2011.03457.x

        (received, 2014-12-05; accepted, 2014-12-12)

        Tammy Saah, MD, is a senior associate and the first Treatment Resistant Depression Fellow in the Department of Psychiatry and Behavioral Sciences at Emory University. Dr. Saah is involved in the development of the Treatment Resistant Depression (TRD) Clinic at Emory and a supervisor in the department’s Dialectical Behavior Therapy group. Dr. Saah’s clinical and research interests are focused in TRD, with an emphasis on advanced psychopharmacology, novel therapeutics, and neuromodulation.

        抗抑郁藥聯(lián)合治療之前應(yīng)考慮各種單藥優(yōu)化治療方案

        Saah T, Garlow SJ, Rapaport MH

        許多慢性抑郁癥患者或反復(fù)發(fā)作的抑郁癥患者對(duì)現(xiàn)有的各種抗抑郁藥物治療反應(yīng)不理想。醫(yī)生在治療這些患者時(shí),可能在原來抗抑郁藥物的基礎(chǔ)上增加其他藥物,包括用第二種或第三種抗抑郁藥物輔助治療。雖然在高收入國(guó)家這是精神科醫(yī)生和初級(jí)保健醫(yī)生廣泛使用的方法,但是證明這種抗抑郁藥聯(lián)合治療方法有效的證據(jù)不多。只有當(dāng)不同種類的抗抑郁藥物的單藥優(yōu)化治療方案無效后,才可謹(jǐn)慎使用聯(lián)合治療的方法。

        抗抑郁藥,聯(lián)合治療,增效,抑郁癥,難治性抑郁癥

        Summary:Many patients with chronic or recurring major depressive disorder have suboptimal responses to the wide range of antidepressant medications available. When confronted with these patients, clinicians may augment the original antidepressant with other medications, including adjunctive treatment with a second or third antidepressant. Although it is a widely-used practice among psychiatrists and primary care physicians in high-income countries, evidence for the benefits of this type of antidepressant polypharmacy is limited. Care should be taken to utilize this approach only after failure of optimized monotherapy with different classes of antidepressants.

        [Shanghai Arch Psychiatry.2014;26(6): 360-362.

        http://dx.doi.org/10.11919/j.issn.1002-0829.214182]

        Department of Psychiatry and Behavioral Sciences, Emory University, Georgia, United States

        *correspondence: tammy.saah@emory.edu

        A full-text Chinese translation of this article will be available at www.shanghaiarchivesofpsychiatry.org on January 25, 2015.

        for preparing this commentary.

        本文全文中文版從2015年01月25日起在www.shanghaiarchivesofpsychiatry.org可供免費(fèi)閱覽下載

        猜你喜歡
        單藥抗抑郁精神科
        抗抑郁藥帕羅西汀或可用于治療骨關(guān)節(jié)炎
        中老年保健(2021年5期)2021-12-02 15:48:21
        精神科護(hù)理工作研究進(jìn)展
        恩替卡韋在阿德福韋單藥治療患者中的應(yīng)用
        肝博士(2021年1期)2021-03-29 02:32:12
        恩替卡韋在阿德福韋酯單藥治療患者中的應(yīng)用
        肝博士(2020年5期)2021-01-18 02:50:22
        當(dāng)藥黃素抗抑郁作用研究
        頤腦解郁顆??挂钟糇饔眉捌錂C(jī)制
        中成藥(2018年4期)2018-04-26 07:12:39
        舒肝解郁膠囊的抗抑郁作用及其機(jī)制
        中成藥(2018年1期)2018-02-02 07:20:16
        唑來膦酸單藥治療肺癌骨轉(zhuǎn)移患者的療效及不良反應(yīng)
        精神科醫(yī)護(hù)人員職業(yè)倦怠相關(guān)分析
        精神科醫(yī)院安全隱患多
        日韩无码电影| 亚洲中文字幕在线第二页| 久久人人玩人妻潮喷内射人人 | 国产成人一区二区三区在线观看| 久久精品国产亚洲婷婷| 最新国产成人自拍视频| 国产夫妻自拍视频在线播放| 最近2019年好看中文字幕视频| 精品久久久久久久久久久aⅴ| 欧美巨大xxxx做受中文字幕| 蜜桃av中文字幕在线观看| 美女被插到高潮嗷嗷叫| 国产成人大片在线播放| 亚洲av永久无码精品三区在线| 色综合久久久久久久久五月| 淫妇日韩中文字幕在线| 婷婷丁香开心五月综合| 亚洲人成无码区在线观看| 久久精品国产www456c0m| 精品一区二区av天堂| 国产网友自拍视频在线观看| 一区二区三区中文字幕p站| 无遮挡又爽又刺激的视频| 国产成人8x视频网站入口| 免费在线观看草逼视频| 亚洲三区在线观看内射后入| 亚洲精品欧美二区三区中文字幕| 亚洲人成影院在线高清| 日韩人妖干女同二区三区| 国产69久久精品成人看| 天天躁日日躁狠狠躁av中文| 亚洲AV无码永久在线观看| 白嫩少妇在线喷水18禁| 久久亚洲精品国产亚洲老地址| 亚洲色欲久久久久综合网| 亚洲色四在线视频观看| 亚洲一区域二区域三区域四| 波多野结衣av一区二区全免费观看 | 国产自拍一区二区三区| 亚洲熟女综合色一区二区三区| 中文字幕亚洲乱码熟女在线萌芽|